Calabadion: A new agent to reverse the effects of benzylisoquinoline and steroidal neuromuscular-blocking agents Post date May 13, 2022 Tags Benzylisoquinoline, Calabadion, Steroidal neuromuscular ← Spreading depression and the clinical correlates of migraine → Subarachnoid hemorrhage, spreading depolarizations and impaired neurovascular coupling
Neurovascular Research UnitNeurovascular Research Unit